2026-04-05T12:52:43Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4556572026-03-21T03:21:56Zcom_2072_98col_2072_378192

00925njm 22002777a 4500 dc Bellido, Virginia author Pérez Pérez, Antonio author Universitat Autònoma de Barcelona author 2020 Diabetes is one of the most common comorbidities in hospitalized patients with coronavirus disease 2019 (COVID-19). Inpatient hyperglycemia during this pandemic has been associated with worse outcomes, so it is mandatory to implement effective glycemic control treatment approaches for inpatients with COVID-19. The shortage of personal protective equipment, the need to prevent staff exposure, or the fact that many of the healthcare professionals might be relatively unfamiliar with the management of hyperglycemia may lead to worse glycemic control and, consequently, a worse prognosis. In order to reduce these barriers, we intend to adapt established recommendations to manage hyperglycemia during this pandemic in critical and noncritical care settings. COVID-19 Diabetes Hospitalized Hyperglycemia Inpatient Insulin therapy SARS-CoV-2 Inpatient Hyperglycemia Management and COVID-19